Quick Answer
Roivant Sciences Ltd. reported Cash and Equivalents of $2.72 billion for fiscal year 2025.
Roivant Sciences Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.72B | -58.2% |
| 2024 | $6.49B | +287.3% |
| 2023 | $1.68B | -18.6% |
| 2022 | $2.06B | +0.3% |
| 2021 | $2.06B | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.48B | -25.7% | +19.5% |
| September 30, 2025 | $1.24B | -36.8% | -0.1% |
| June 30, 2025 | $1.24B | -78.2% | -54.4% |
| March 31, 2025 | $2.72B | -58.2% | +36.4% |
| December 31, 2024 | $1.99B | -70.2% | +1.6% |
| September 30, 2024 | $1.96B | +39.1% | -65.5% |
| June 30, 2024 | $5.68B | +296.0% | -12.6% |
| March 31, 2024 | $6.49B | +287.3% | -2.6% |
- Roivant Sciences Ltd. showed a decrease of -58.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Roivant Sciences Ltd.’s cash and equivalents has grown by 32.1% (from $2.06 billion to $2.72 billion).
- The most recent figure is from Roivant Sciences Ltd.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: